A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/Day Monotherapy in Subjects With Partial-onset Seizures

Trial Profile

A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/Day Monotherapy in Subjects With Partial-onset Seizures

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Lacosamide (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ALEX-MT
  • Sponsors UCB
  • Most Recent Events

    • 20 Apr 2015 Post-hoc analysis results presented at the 67th Annual Meeting of the American Academy of Neurology (AAN), according to a UCB media release.
    • 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 05 Mar 2013 Full efficacy and safety results will be presented at an upcoming epilepsy meeting, according to a UCB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top